Two out of the fifty studies included in the meta-analysis utilized the SP263 antibody—Igawa et al. observed no association of PD-L1 with survival in stage I-III patients45, whereas Wu et al. documented lower survival associated with PD-L1 expression in a cohort of stage I-IV NSCLC patients46, though estimates were imprecise. Here, CD274 is linked to non-small cell lung carcinoma.